37 million Arab-Amazigh people in Africa’s most strategically positioned research market; Law 28-13’s France-aligned biomedical research framework, Casablanca as Francophone Africa’s pharmaceutical industry hub, world-leading Amazigh population pharmacogenomics, and French-language clinical practice connecting Morocco to European research conventions.
Morocco is a constitutional monarchy of approximately 37 million people; the Maghreb’s most populous country and Africa’s westernmost nation; occupying 446,550 km² of strategic Atlantic-Mediterranean territory at the continent’s northern tip, separated from Spain by only 14 kilometres across the Strait of Gibraltar. Morocco’s geography encompasses the fertile Atlantic coastal plains where Casablanca (~6 million metropolitan) and Rabat (~1.5 million; the administrative capital) anchor the country’s economic and research infrastructure; the Middle and High Atlas Mountains dividing the country from north to south; the ancient imperial cities of Fes (~1.2 million metropolitan; the historic intellectual and medical education capital), Marrakech (~1.1 million), and Meknes; the northern Rif Mountains and Mediterranean coast; and the pre-Saharan and Saharan south. Morocco’s position at the crossroads of Europe, West Africa, and the Arab world has made Casablanca the financial capital of Francophone Africa and the preferred location for multinational pharmaceutical company regional headquarters covering the MENA and Africa markets simultaneously; with Sanofi, Roche, Novartis, GSK, Pfizer, AstraZeneca, and dozens of other global pharmaceutical companies maintaining their Africa or MENA regional operations from Casablanca’s Casablanca Finance City (CFC). This pharmaceutical industry concentration creates a research activation ecosystem; established local medical science liaison networks, pre-approved regulatory submissions pathways, and experienced investigator relationships; that substantially reduces the first-site activation effort for sponsors entering Morocco compared to other Maghreb or Arab Mashreq research markets. Morocco is politically stable, governed by King Mohammed VI (since 1999) under a constitutional monarchy whose moderate, reform-oriented governance has created one of Africa’s most attractive business environments, and whose investment in healthcare infrastructure is progressively building the hospital capacity that Morocco’s research growth requires.
Clinical trials in Morocco are regulated under Law 28-13 (Loi relative à la protection des personnes qui se prêtent à la recherche biomédicale); enacted in 2015 with implementing regulations in 2017; and are managed by the Direction du Médicament et de la Pharmacie (DMP) under the Ministère de la Santé et de la Protection Sociale, working in parallel with the national ethics body CERB (Comité d’Ethique pour la Recherche Biomédicale) and institutional ethics committees at major teaching hospitals. Law 28-13 is the most structurally comprehensive dedicated biomedical research law in the Arab world; modelled explicitly on France’s Loi Jardé framework, defining research categories (interventional, minimal risk, non-interventional), establishing proportionate review processes, codifying sponsor-investigator responsibilities, and aligning informed consent requirements with international Declaration of Helsinki standards. This legal architecture, conducting regulatory review primarily in French (with English submissions also accepted), creates a pharmaceutical regulatory environment whose conventions are more compatible with French, Belgian, and Swiss pharmaceutical regulatory practice than any other Arab MENA country’s framework. Clinical trial approval timelines are approximately 3–5 months for standard Phase II–III applications. The Moroccan Dirham (MAD) is a managed floating currency providing a competitive exchange rate for EUR/USD-denominated budgets.
Morocco’s 37 million people carry one of the most pharmacogenomically complex genetic profiles of any single national population in the Arab world; shaped by the interaction of two major ancestral groups: the indigenous Amazigh (Berber) population, the pre-Arab inhabitants of North Africa whose genetic ancestry dates to at least the Upper Palaeolithic and whose lineages persist in highest proportions in the High Atlas, Middle Atlas, Rif Mountains, and southern Morocco; and the Arab population whose ancestry traces to the 7th–11th century Arab conquests and subsequent centuries of inter-marriage. Estimates of Morocco’s Amazigh population vary widely (from 40% to 60% Amazigh-speaking depending on definition), but Morocco is unambiguously home to the world’s largest Amazigh-speaking population; approximately 14–16 million people speaking Tamazight (officially co-official language since 2011) in its Tachelhit (south), Tamazight (central Atlas), and Tarifit (Rif) variants. The Arab-majority population is concentrated in the coastal cities and plains of northern and central Morocco. Sub-Saharan African genetic ancestry; from historic trans-Saharan trade routes, the Haratin communities of southern Morocco, and more recent Sub-Saharan African migration; adds a third distinct ancestral component in southern regions near the Western Sahara. Morocco’s Amazigh communities also carry the highest frequencies in North Africa of certain genetic conditions including G6PD (glucose-6-phosphate dehydrogenase) deficiency variants that differ from the West African or Mediterranean G6PD deficiency alleles, creating important pharmacogenomic considerations for drugs that trigger haemolysis in G6PD-deficient patients. French is the dominant language of higher education, medicine, pharmaceutical research, and business; Darija (Moroccan Arabic) is the daily spoken language; Modern Standard Arabic and Tamazight are both official languages. The Moroccan physician community is heavily Francophone; the vast majority trained in French-medium medical schools; with a significant proportion holding postgraduate degrees from France, Belgium, or Switzerland, creating an internationally oriented investigator community whose research culture is more closely aligned with French and Belgian GCP standards than with Anglo-American conventions.
Morocco’s disease burden reflects the non-communicable disease transition of a rapidly urbanising middle-income country overlaid with specific infectious and genetic disease patterns of the Maghreb-Saharan ecology. Cardiovascular disease leads mortality at approximately 34% of deaths; hypertension affects roughly 30% of adults, and coronary artery disease is growing sharply with dietary change, tobacco use, and metabolic risk factor accumulation. Cancer is the second leading cause, with breast cancer the most common malignancy in Moroccan women (with a median age of onset 5–10 years younger than in European reference populations), colorectal cancer growing rapidly with diet Westernisation, and prostate cancer the most common malignancy in men; the Institut National d’Oncologie (INO) in Rabat manages Morocco’s national cancer registry and Phase II–IV oncology trial portfolio. Type 2 diabetes affects approximately 10–12% of adults; a significant rate for North Africa; with very high abdominal obesity prevalence particularly among urban Moroccan women driving NASH and metabolic syndrome. Tuberculosis remains a meaningful public health burden; Morocco reports approximately 30,000 new TB cases annually, one of North Africa’s highest burdens; creating a research platform for TB therapeutic trials and drug-resistant TB programs that, combined with the INH (isoniazid) pharmacogenomics of Morocco’s NAT2-polymorphic Amazigh population, provides a scientifically distinctive TB research environment. Mental health; depression, anxiety, and schizophrenia; carries significant and underrecognised burden. Haemoglobinopathies including sickle cell disease (in southern Morocco’s communities with Sub-Saharan African admixture) and thalassaemia (in Mediterranean-ancestry northern coastal communities) are present at relevant clinical frequencies in specific regional populations.
Morocco’s Amazigh pharmacogenomics; the world’s most important North African Berber pharmacogenomic research population and what it means for drug developers: The Amazigh (Berber) populations of Morocco represent the world’s largest concentration of North African indigenous genetic ancestry; estimated at 14–16 million people whose pharmacogenomic profiles have been documented by international consortia including the Human Genome Diversity Project (HGDP, which includes Moroccan Berber samples as one of its 52 reference populations), the North African Genome Project, and published pharmacogenomics studies in Clinical Pharmacology and Therapeutics, The Pharmacogenomics Journal, and other peer-reviewed journals. The Amazigh pharmacogenomic profile is not interchangeable with Arab Gulf, Levantine Arab, or European reference populations; in ways that have direct clinical implications for drug development. NAT2 (N-acetyltransferase 2): Moroccan Berber populations carry distinct slow-acetylator allele frequencies; important for isoniazid (TB treatment), sulfamethoxazole, procainamide, dapsone, and several oncology agents; whose North African frequencies differ from both the European and the Gulf Arab NAT2 references used in most pharmacogenomic sub-study designs. CYP2D6: The frequency of poor-metabolizer alleles (particularly CYP2D6*4 and CYP2D6*17) in Amazigh populations creates codeine, tramadol, tamoxifen, and antipsychotic metabolism patterns that have been documented as distinct from European cohort data. CYP2C19: Berber populations have poor- and ultra-rapid-metabolizer allele frequencies that affect proton pump inhibitor, clopidogrel, and antidepressant dosing pharmacology in ways that North African Berber-specific data has documented as clinically relevant. G6PD deficiency: Moroccan Amazigh communities carry specific G6PD deficiency alleles; the Mediterranean variant and certain Africa-specific variants; at frequencies that make Morocco essential for sponsors developing drugs with known G6PD-mediated haemolysis risk. The regulatory implication is direct: for sponsors seeking FDA or EMA approval for drugs where pharmacogenomics significantly affects therapeutic response or safety; and where North African populations are a target market; Morocco’s CHU network, Institut National d’Oncologie, and Facultés de Médecine de Rabat, Fes, and Marrakech provide the world’s only large-scale, research-capable platform for Amazigh pharmacogenomic sub-studies within commercial Phase II–III programmes that no other Arab country can replicate.
Morocco’s research proposition rests on four elements that differentiate it from every other Maghrebi, African, and Arab MENA research market: Law 28-13’s France-modelled biomedical research framework; the Arab world’s most structurally advanced regulatory law for clinical trials; creating the most EU-compatible research legal environment in the Arab world; Casablanca’s unique status as Francophone Africa’s pharmaceutical industry headquarters giving Morocco established multinational trial activation infrastructure; the world’s largest Amazigh pharmacogenomic research population whose North African Berber genetics are irreplaceable for certain drug development programs; and a three-city research triangle (Casablanca-Rabat-Fes) that distributes Morocco’s 37 million people across three major academic medical research nodes with no equivalent multi-hub structure in the Maghreb.
DMP (Direction du Médicament et de la Pharmacie) oversight under Morocco’s dedicated <strong className="text-primary">Loi 28-13</strong> (2015; implementing decrees 2017); the Arab world’s most comprehensive dedicated biomedical research law, explicitly modelled on France’s Loi Jardé; defining research categories, CERB national ethics oversight, sponsor-investigator responsibilities, and informed consent standards aligned with international Declaration of Helsinki requirements; French-language regulatory submissions broadly compatible with French, Belgian, and Swiss pharmaceutical regulatory practice; English also accepted; institutional ethics committees at all CHU hospitals; approval timelines approximately 3–5 months; the most structurally France-comparable regulatory environment in any Arab Maghreb country.
Casablanca Finance City (CFC) hosts Francophone Africa’s highest concentration of multinational pharmaceutical company MENA/Africa regional headquarters; Sanofi, Roche, Novartis, GSK, Pfizer, AstraZeneca, and others; creating pre-established investigator networks, site feasibility databases, and regulatory submission experience that dramatically reduces trial activation overhead for sponsors already operating in Morocco commercially; Mohammed V International Airport hub (direct connections to Paris, Amsterdam, Brussels, Madrid, London, New York, Dubai, Doha); per-patient and operational costs significantly below Gulf countries and competitive with North African peers; MAD exchange rate advantageous for EUR/USD budgets; compact three-city research corridor minimising internal logistics.
37M Arab-Amazigh population; the Maghreb’s largest; with the world’s most significant Amazigh pharmacogenomic study population (~14–16M Amazigh speakers; distinct NAT2, CYP2D6, CYP2C19, and G6PD profiles); ~30,000 annual TB cases creating a North African MDR-TB research platform; T2D 10–12% of adults with growing NASH/NAFLD; high cardiovascular burden; significant cancer burden (INO Rabat oncology platform); SCD in southern communities (Sub-Saharan admixture); thalassaemia in northern coastal populations; large treatment-naïve pools across all NCD categories; Amazigh pharmacogenomics irreplaceable for North African drug-specific sub-studies.
Casablanca-Rabat-Fes research triangle; unique in the Maghreb; distributing Morocco’s research infrastructure across three major nodes: <strong className="text-primary">Rabat</strong> (CHU Ibn Sina; Morocco’s largest public hospital; INO national cancer institute; national specialty institutes; government regulatory authorities); <strong className="text-primary">Casablanca</strong> (CHU Ibn Rochd; Institut Pasteur du Maroc; private hospital research cluster; multinational pharma industry ecosystem); <strong className="text-primary">Fes</strong> (CHU Hassan II; Faculté de Médecine et de Pharmacie de Fes; Morocco’s most research-productive medical school per faculty output); plus CHU Mohammed VI anchors in Marrakech and Oujda; 6 CHU complexes covering all major Moroccan regions.
Cardiovascular disease; Morocco’s leading cause of mortality at approximately 34% of deaths; is the most commercially dominant research pillar in a patient population whose cardiovascular risk factor profile combines very high hypertension prevalence (~30% of adults), growing dyslipidaemia and coronary artery disease as dietary patterns Westernise, and elevated tobacco use among men (~40% male smoking prevalence); CHU Ibn Sina’s cardiology and cardiac surgery departments and CHU Ibn Rochd’s cardiovascular programme anchor Phase II–III cardiovascular outcome and device trial activity in a patient population whose Arab-Amazigh genetics create cardiovascular disease presentations distinct from European or Gulf Arab reference populations in pharmacogenomically relevant ways. Oncology is Morocco’s second major commercial pillar; anchored by the Institut National d’Oncologie (INO) in Rabat, which manages Morocco’s national cancer registry and runs the country’s most active oncology Phase II–IV commercial trial portfolio; covering breast cancer (Morocco’s most common malignancy in women, with a median age at diagnosis 5–10 years younger than European populations, creating large treatment-naïve pools in the 40–55 age range for neoadjuvant and adjuvant trial designs), colorectal cancer, prostate cancer, and haematological malignancies including lymphoma and leukaemia; INO’s membership in Francophone oncology research networks (French cooperative groups, Organisation Internationale de la Francophonie health research programmes) creates Phase II–III cooperative group trial activation channels that anglophone Arab research markets do not access. Tuberculosis is Morocco’s most scientifically distinctive infectious disease research pillar; approximately 30,000 new TB cases annually place Morocco among North Africa’s highest-burden countries; and the intersection of significant MDR-TB rates with the NAT2 slow-acetylator pharmacogenomics of Morocco’s Amazigh population creates a TB pharmacogenomics research environment of global scientific interest: Amazigh-ancestry TB patients metabolising isoniazid through the slow-acetylator NAT2 pathway have isoniazid pharmacokinetics and treatment-outcome patterns that cannot be extrapolated from European, South Asian, or sub-Saharan African reference data. Metabolic disease (T2D, NASH, obesity), pharmacogenomics (Amazigh NAT2, CYP2D6, CYP2C19, G6PD; the world reference platform), mental health and psychiatry (the Hôpital Arrazi programme and Morocco’s significant psychiatric burden), respiratory medicine (COPD, asthma, TB overlap), and haematology (SCD in southern communities, thalassaemia in Mediterranean-ancestry northern populations) complete a research portfolio that is the Maghreb’s broadest and most commercially accessible, anchored by Law 28-13’s legal architecture and Casablanca’s pharmaceutical industry ecosystem.
Morocco’s research geography is defined by its three-city triangle: Rabat concentrates the national specialty institutes (INO, Hôpital des Spécialités, Hôpital Militaire) and the CHU Ibn Sina complex that serves as the national referral anchor; Casablanca provides access to the economic capital’s six-million-person metropolitan patient pool through CHU Ibn Rochd and an established private hospital research cluster backed by the multinational pharmaceutical industry ecosystem; Fes is Morocco’s academic medical research powerhouse, whose Faculté de Médecine et de Pharmacie de Fes has produced a disproportionate share of Morocco’s international pharmacogenomics publications. The four remaining CHU complexes in Marrakech, Oujda, Agadir, and the Tangier corridor extend Morocco’s research geography across the Atlantic coast, the eastern Algerian border corridor, and the southern Pre-Saharan regions; each providing distinct patient demographics reflecting Morocco’s extraordinary regional diversity.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | CHU Ibn Sina | Rabat | Morocco’s largest and most complex public hospital complex; affiliated with Mohammed V University’s Faculté de Médecine et de Pharmacie de Rabat and serving as the national referral centre for multi-specialty complex cases; with Phase I–IV commercial trial activity across cardiovascular, haematology, nephrology, hepatology, endocrinology, internal medicine, and paediatrics; CHU Ibn Sina’s integrated campus in Rabat encompasses multiple specialist hospitals (including Hôpital Ibn Sina, Hôpital Avicenne, Hôpital d’Enfants, and Hôpital Maternité Souissi) providing a multi-specialty research environment within a single institutional ethics committee framework; as Morocco’s primary national referral centre, CHU Ibn Sina’s patient catchment spans all 12 Moroccan regions, creating enrollment access to the full diversity of Moroccan Arab-Amazigh patient demographics; from the Atlantic coastal plains’ Arab-dominant urban population to the Atlas Mountains’ Amazigh-majority rural communities; within a single Rabat campus. |
| 02 | Institut National d’Oncologie (INO) | Rabat | Morocco’s national cancer institute; the primary oncology Phase I–IV research institution in Morocco and the custodian of the national cancer registry covering all 12 Moroccan regions; with an active commercial Phase II–IV trial portfolio spanning breast cancer (Morocco’s most clinically distinctive oncology niche; younger age of onset, proportionally higher triple-negative disease burden, large treatment-naïve pool), colorectal cancer, prostate cancer, haematological malignancies (lymphoma, leukaemia, myeloma), and gynaecological cancers; INO’s national cancer registry database provides pre-trial oncology feasibility data of exceptional precision for a country of Morocco’s size; enabling exact patient number estimates before site activation; and its membership in Francophone oncology research networks (French cooperative groups, EORTC observer status) creates Phase III cooperative group trial channels complementary to the anglophone oncology research networks dominating most Mashreq and Gulf Arab markets. |
| 03 | Hôpital Militaire d’Instruction Mohammed V (HMIMV) | Rabat | Morocco’s premier military teaching hospital; one of the most technically advanced hospital facilities in the country, benefiting from military capital investment that has historically provided more consistent equipment and infrastructure than the MOH public hospital system; and a significant Phase II–III research site across cardiovascular, oncology, internal medicine, and infectious disease (including TB research reflecting Morocco’s significant TB burden); HMIMV’s patient base; serving Royal Moroccan Armed Forces personnel, veterans, and their families across a structured, systematically enrolled healthcare population; provides research access to a physically active, younger-skewing demographic whose systematically maintained health records and high institutional compliance rates create favorable trial execution conditions; its research ethics committee and established pharmaceutical company research relationships sustain an active commercial Phase II–III portfolio complementary to the CHU civilian research network. |
| 04 | Hôpital des Spécialités de Rabat | Rabat | Rabat’s national specialty hospital; Morocco’s primary referral centre for neurology, neurosurgery, ophthalmology, ENT, and rare diseases; affiliated with Mohammed V University and conducting Phase II–III research in neurological conditions, CNS disorders, rare genetic diseases (including conditions arising from Amazigh-community consanguinity in Atlas mountain populations referred to Rabat for specialist care), and specialty medicine; Hôpital des Spécialités’ neurological research programme reflects the growing burden of Alzheimer’s disease, multiple sclerosis, epilepsy, and Parkinson’s disease in Morocco’s ageing urban population; its rare disease programme; managing the full spectrum of genetic conditions from Morocco’s consanguineous Atlas Amazigh communities; is the primary Moroccan institutional partner for rare disease drug development programmes requiring North African Berber ancestry patient populations. |
| 05 | CHU Ibn Rochd | Casablanca | Casablanca’s primary teaching hospital; affiliated with Hassan II University’s Faculté de Médecine et de Pharmacie de Casablanca and serving Morocco’s most populous metropolitan area (~6 million); with Phase II–IV commercial trial activity across cardiovascular, oncology, hepatology (HBV, HCV, NAFLD), metabolic disease, and internal medicine; CHU Ibn Rochd’s Casablanca location; at the heart of Francophone Africa’s pharmaceutical industry hub; provides the most direct connection between Morocco’s largest patient population and the multinational pharmaceutical company regional offices whose established investigator relationships, site feasibility data, and Law 28-13 submission experience substantially reduce trial activation timelines; its large urban patient catchment from Casablanca’s diverse metropolitan population; spanning the city’s industrial working-class districts and professional suburbs; provides research access to Morocco’s broadest socioeconomic spectrum within a single institution. |
| 06 | Institut Pasteur du Maroc | Casablanca | Morocco’s primary infectious disease research institution; a member of the Institut Pasteur International Network based in Casablanca; conducting research in TB, viral hepatitis (HBV, HCV), arboviral infections (West Nile virus, dengue), rabies, brucellosis, leishmaniasis, and antimicrobial resistance; Institut Pasteur du Maroc’s national reference laboratory network; providing pathogen identification, serological surveillance, and molecular typing for Morocco’s 12 regional health directorates; creates infectious disease epidemiological data of exceptional national coverage that underpins clinical trial feasibility for infectious disease programs; its WHO partnerships and Pasteur International Network connections link Moroccan infectious disease research to global surveillance and therapeutic development programmes; an important institutional partner for TB drug and vaccine trials, antiparasitic development (leishmaniasis, Chagas-disease-related research), and emerging Mediterranean arboviral surveillance studies. |
| 07 | CHU Hassan II; Fes | Fes | Morocco’s most academically productive teaching hospital; affiliated with Sidi Mohammed Ben Abdallah University’s Faculté de Médecine et de Pharmacie de Fes (FMPM), recognised as Morocco’s most research-intensive medical school per faculty member by international publication metrics; with Phase II–IV commercial trial activity across haematology (Morocco’s most active haematology research programme, with particular expertise in lymphoma, leukaemia, and the haemoglobinopathies of Fes’s mixed Arab-Amazigh Atlas-fringe patient population), oncology, cardiovascular, and internal medicine; the FMPM has been the primary Moroccan academic institution in published Amazigh pharmacogenomics research; including studies of NAT2 polymorphisms in Moroccan Berber TB patients and CYP2D6 variant frequencies in Moroccan Amazigh communities; making CHU Hassan II Fes the most scientifically credentialed site for commercial Phase II–III pharmacogenomics sub-studies targeting North African Berber populations. |
| 08 | CHU Mohammed VI; Marrakech | Marrakech | Marrakech’s university teaching hospital; affiliated with Cadi Ayyad University’s Faculté de Médecine et de Pharmacie de Marrakech; and Morocco’s southern research anchor, serving the approximately 5 million people of the Marrakech-Safi and Draa-Tafilalet regions; Phase II–III research activity across cardiovascular, oncology, metabolic disease, and internal medicine; CHU Mohammed VI Marrakech’s patient catchment from the High Atlas foothill communities and the pre-Saharan southern plains provides access to Morocco’s most Amazigh-ancestry-concentrated patient demographics outside Fes; the Tachelhit-speaking communities of the Souss-Massa and High Atlas regions whose Amazigh genetic proportions are among the highest in the country; making CHU Marrakech an important secondary site for sponsors designing Amazigh pharmacogenomic sub-studies requiring patient enrollment from Morocco’s southern Berber heartland. |
| 09 | CHU Mohammed VI; Oujda | Oujda | Eastern Morocco’s university teaching hospital; affiliated with Mohammed Premier University’s Faculté de Médecine et de Pharmacie d’Oujda and serving approximately 2.3 million people in the Oriental region bordering Algeria; with Phase II–III research activity across cardiovascular, oncology, metabolic disease, and infectious disease; CHU Mohammed VI Oujda’s border region location creates specific research opportunities in trans-border infectious disease surveillance (TB, HCV, leishmaniasis in the Morocco-Algeria corridor), migration-related health research, and the distinctive disease burden of Morocco’s eastern populations whose genetic profile reflects the historical Berber-Arab contact zones of the eastern Rif and the Algerian Tlemcen corridor; an important eastern Morocco research site for sponsors designing Morocco-wide Phase III programs requiring patient coverage across all major regional demographics. |
| 10 | CHU Souss-Massa | Agadir | Southern Morocco’s university teaching hospital; affiliated with the Faculté de Médecine et de Pharmacie d’Agadir (Ibn Zohr University) and serving approximately 2.6 million people in the Souss-Massa and Guelmim-Oued Noun regions; with Phase II–III research activity across cardiovascular, oncology, internal medicine, and infectious disease; CHU Souss-Massa’s Agadir location in Morocco’s Souss valley; the heartland of Tachelhit-speaking Amazigh culture, where Amazigh genetic proportions are among the highest in North Africa; creates the most geographically concentrated Amazigh pharmacogenomic patient access of any Moroccan CHU; for sponsors designing Amazigh-specific NAT2, CYP2D6, or G6PD sub-studies within Phase II–III programmes, CHU Souss-Massa provides the southern Atlas population research access that complements FMPM Fes’s central Atlas Amazigh patient base; its proximity to the Atlantic coast and Agadir’s growing international healthcare profile adds operational accessibility. |
| 11 | Hôpital Cheikh Khalifa Ibn Zaid | Casablanca | One of Casablanca’s most modern hospital facilities; constructed with Emirati philanthropic funding and managed through a public-private partnership; providing a technologically advanced research environment within Casablanca’s pharmaceutical industry hub; Phase II–III commercial trial activity across oncology, cardiovascular, internal medicine, and metabolic disease; Hôpital Cheikh Khalifa’s modern infrastructure; including GCP-compliant clinical research facilities, electronic data capture readiness, and direct adjacency to Casablanca’s pharmaceutical company regional offices; provides a private-sector research complement to CHU Ibn Rochd’s public hospital environment, attracting a middle-to-upper-income Casablanca patient demographic whose socioeconomic profile and research participation expectations differ from the public hospital catchment; its newer research office and institutional ethics committee have been progressively building a commercial Phase II–III portfolio aligned with Law 28-13’s requirements. |
| 12 | Hôpital Arrazi (Établissement Psychiatrique de Salé) | Salé | Morocco’s largest psychiatric hospital; located in Salé, directly adjacent to the capital Rabat, and affiliated with Mohammed V University through the national mental health research programme; and the primary Phase II–III research site for psychopharmacology, psychiatric disorder clinical trials, and mental health intervention programmes in Morocco; Hôpital Arrazi’s large inpatient and outpatient psychiatric catchment; serving Morocco’s growing and significantly underrecognised mental health disease burden across schizophrenia, depression, anxiety, and bipolar disorder; provides research access to the Arab-Amazigh North African psychiatric patient population whose psychopharmacological drug metabolism (antipsychotics, antidepressants; primarily CYP2D6 and CYP2C19 substrates) is shaped by the Amazigh pharmacogenomic profiles that distinguish Moroccan patients from European or Gulf Arab psychiatric drug metabolism references; an irreplaceable site for sponsors developing CNS drugs requiring Moroccan North African Amazigh pharmacogenomic data within psychiatric Phase II–III programmes. |
Morocco’s largest and most complex public hospital complex; affiliated with Mohammed V University’s Faculté de Médecine et de Pharmacie de Rabat and serving as the national referral centre for multi-specialty complex cases; with Phase I–IV commercial trial activity across cardiovascular, haematology, nephrology, hepatology, endocrinology, internal medicine, and paediatrics; CHU Ibn Sina’s integrated campus in Rabat encompasses multiple specialist hospitals (including Hôpital Ibn Sina, Hôpital Avicenne, Hôpital d’Enfants, and Hôpital Maternité Souissi) providing a multi-specialty research environment within a single institutional ethics committee framework; as Morocco’s primary national referral centre, CHU Ibn Sina’s patient catchment spans all 12 Moroccan regions, creating enrollment access to the full diversity of Moroccan Arab-Amazigh patient demographics; from the Atlantic coastal plains’ Arab-dominant urban population to the Atlas Mountains’ Amazigh-majority rural communities; within a single Rabat campus.
Morocco’s national cancer institute; the primary oncology Phase I–IV research institution in Morocco and the custodian of the national cancer registry covering all 12 Moroccan regions; with an active commercial Phase II–IV trial portfolio spanning breast cancer (Morocco’s most clinically distinctive oncology niche; younger age of onset, proportionally higher triple-negative disease burden, large treatment-naïve pool), colorectal cancer, prostate cancer, haematological malignancies (lymphoma, leukaemia, myeloma), and gynaecological cancers; INO’s national cancer registry database provides pre-trial oncology feasibility data of exceptional precision for a country of Morocco’s size; enabling exact patient number estimates before site activation; and its membership in Francophone oncology research networks (French cooperative groups, EORTC observer status) creates Phase III cooperative group trial channels complementary to the anglophone oncology research networks dominating most Mashreq and Gulf Arab markets.
Morocco’s premier military teaching hospital; one of the most technically advanced hospital facilities in the country, benefiting from military capital investment that has historically provided more consistent equipment and infrastructure than the MOH public hospital system; and a significant Phase II–III research site across cardiovascular, oncology, internal medicine, and infectious disease (including TB research reflecting Morocco’s significant TB burden); HMIMV’s patient base; serving Royal Moroccan Armed Forces personnel, veterans, and their families across a structured, systematically enrolled healthcare population; provides research access to a physically active, younger-skewing demographic whose systematically maintained health records and high institutional compliance rates create favorable trial execution conditions; its research ethics committee and established pharmaceutical company research relationships sustain an active commercial Phase II–III portfolio complementary to the CHU civilian research network.
Rabat’s national specialty hospital; Morocco’s primary referral centre for neurology, neurosurgery, ophthalmology, ENT, and rare diseases; affiliated with Mohammed V University and conducting Phase II–III research in neurological conditions, CNS disorders, rare genetic diseases (including conditions arising from Amazigh-community consanguinity in Atlas mountain populations referred to Rabat for specialist care), and specialty medicine; Hôpital des Spécialités’ neurological research programme reflects the growing burden of Alzheimer’s disease, multiple sclerosis, epilepsy, and Parkinson’s disease in Morocco’s ageing urban population; its rare disease programme; managing the full spectrum of genetic conditions from Morocco’s consanguineous Atlas Amazigh communities; is the primary Moroccan institutional partner for rare disease drug development programmes requiring North African Berber ancestry patient populations.
Casablanca’s primary teaching hospital; affiliated with Hassan II University’s Faculté de Médecine et de Pharmacie de Casablanca and serving Morocco’s most populous metropolitan area (~6 million); with Phase II–IV commercial trial activity across cardiovascular, oncology, hepatology (HBV, HCV, NAFLD), metabolic disease, and internal medicine; CHU Ibn Rochd’s Casablanca location; at the heart of Francophone Africa’s pharmaceutical industry hub; provides the most direct connection between Morocco’s largest patient population and the multinational pharmaceutical company regional offices whose established investigator relationships, site feasibility data, and Law 28-13 submission experience substantially reduce trial activation timelines; its large urban patient catchment from Casablanca’s diverse metropolitan population; spanning the city’s industrial working-class districts and professional suburbs; provides research access to Morocco’s broadest socioeconomic spectrum within a single institution.
Morocco’s primary infectious disease research institution; a member of the Institut Pasteur International Network based in Casablanca; conducting research in TB, viral hepatitis (HBV, HCV), arboviral infections (West Nile virus, dengue), rabies, brucellosis, leishmaniasis, and antimicrobial resistance; Institut Pasteur du Maroc’s national reference laboratory network; providing pathogen identification, serological surveillance, and molecular typing for Morocco’s 12 regional health directorates; creates infectious disease epidemiological data of exceptional national coverage that underpins clinical trial feasibility for infectious disease programs; its WHO partnerships and Pasteur International Network connections link Moroccan infectious disease research to global surveillance and therapeutic development programmes; an important institutional partner for TB drug and vaccine trials, antiparasitic development (leishmaniasis, Chagas-disease-related research), and emerging Mediterranean arboviral surveillance studies.
Morocco’s most academically productive teaching hospital; affiliated with Sidi Mohammed Ben Abdallah University’s Faculté de Médecine et de Pharmacie de Fes (FMPM), recognised as Morocco’s most research-intensive medical school per faculty member by international publication metrics; with Phase II–IV commercial trial activity across haematology (Morocco’s most active haematology research programme, with particular expertise in lymphoma, leukaemia, and the haemoglobinopathies of Fes’s mixed Arab-Amazigh Atlas-fringe patient population), oncology, cardiovascular, and internal medicine; the FMPM has been the primary Moroccan academic institution in published Amazigh pharmacogenomics research; including studies of NAT2 polymorphisms in Moroccan Berber TB patients and CYP2D6 variant frequencies in Moroccan Amazigh communities; making CHU Hassan II Fes the most scientifically credentialed site for commercial Phase II–III pharmacogenomics sub-studies targeting North African Berber populations.
Marrakech’s university teaching hospital; affiliated with Cadi Ayyad University’s Faculté de Médecine et de Pharmacie de Marrakech; and Morocco’s southern research anchor, serving the approximately 5 million people of the Marrakech-Safi and Draa-Tafilalet regions; Phase II–III research activity across cardiovascular, oncology, metabolic disease, and internal medicine; CHU Mohammed VI Marrakech’s patient catchment from the High Atlas foothill communities and the pre-Saharan southern plains provides access to Morocco’s most Amazigh-ancestry-concentrated patient demographics outside Fes; the Tachelhit-speaking communities of the Souss-Massa and High Atlas regions whose Amazigh genetic proportions are among the highest in the country; making CHU Marrakech an important secondary site for sponsors designing Amazigh pharmacogenomic sub-studies requiring patient enrollment from Morocco’s southern Berber heartland.
Eastern Morocco’s university teaching hospital; affiliated with Mohammed Premier University’s Faculté de Médecine et de Pharmacie d’Oujda and serving approximately 2.3 million people in the Oriental region bordering Algeria; with Phase II–III research activity across cardiovascular, oncology, metabolic disease, and infectious disease; CHU Mohammed VI Oujda’s border region location creates specific research opportunities in trans-border infectious disease surveillance (TB, HCV, leishmaniasis in the Morocco-Algeria corridor), migration-related health research, and the distinctive disease burden of Morocco’s eastern populations whose genetic profile reflects the historical Berber-Arab contact zones of the eastern Rif and the Algerian Tlemcen corridor; an important eastern Morocco research site for sponsors designing Morocco-wide Phase III programs requiring patient coverage across all major regional demographics.
Southern Morocco’s university teaching hospital; affiliated with the Faculté de Médecine et de Pharmacie d’Agadir (Ibn Zohr University) and serving approximately 2.6 million people in the Souss-Massa and Guelmim-Oued Noun regions; with Phase II–III research activity across cardiovascular, oncology, internal medicine, and infectious disease; CHU Souss-Massa’s Agadir location in Morocco’s Souss valley; the heartland of Tachelhit-speaking Amazigh culture, where Amazigh genetic proportions are among the highest in North Africa; creates the most geographically concentrated Amazigh pharmacogenomic patient access of any Moroccan CHU; for sponsors designing Amazigh-specific NAT2, CYP2D6, or G6PD sub-studies within Phase II–III programmes, CHU Souss-Massa provides the southern Atlas population research access that complements FMPM Fes’s central Atlas Amazigh patient base; its proximity to the Atlantic coast and Agadir’s growing international healthcare profile adds operational accessibility.
One of Casablanca’s most modern hospital facilities; constructed with Emirati philanthropic funding and managed through a public-private partnership; providing a technologically advanced research environment within Casablanca’s pharmaceutical industry hub; Phase II–III commercial trial activity across oncology, cardiovascular, internal medicine, and metabolic disease; Hôpital Cheikh Khalifa’s modern infrastructure; including GCP-compliant clinical research facilities, electronic data capture readiness, and direct adjacency to Casablanca’s pharmaceutical company regional offices; provides a private-sector research complement to CHU Ibn Rochd’s public hospital environment, attracting a middle-to-upper-income Casablanca patient demographic whose socioeconomic profile and research participation expectations differ from the public hospital catchment; its newer research office and institutional ethics committee have been progressively building a commercial Phase II–III portfolio aligned with Law 28-13’s requirements.
Morocco’s largest psychiatric hospital; located in Salé, directly adjacent to the capital Rabat, and affiliated with Mohammed V University through the national mental health research programme; and the primary Phase II–III research site for psychopharmacology, psychiatric disorder clinical trials, and mental health intervention programmes in Morocco; Hôpital Arrazi’s large inpatient and outpatient psychiatric catchment; serving Morocco’s growing and significantly underrecognised mental health disease burden across schizophrenia, depression, anxiety, and bipolar disorder; provides research access to the Arab-Amazigh North African psychiatric patient population whose psychopharmacological drug metabolism (antipsychotics, antidepressants; primarily CYP2D6 and CYP2C19 substrates) is shaped by the Amazigh pharmacogenomic profiles that distinguish Moroccan patients from European or Gulf Arab psychiatric drug metabolism references; an irreplaceable site for sponsors developing CNS drugs requiring Moroccan North African Amazigh pharmacogenomic data within psychiatric Phase II–III programmes.
Morocco’s pharmaceutical regulatory directorate; operating under the Ministère de la Santé et de la Protection Sociale; governing pharmaceutical product registration, investigational medicinal product import, and clinical trial authorisation under Law 28-13 and ICH GCP E6(R2)-aligned regulations; DMP’s French-language regulatory review process; whose conventions are explicitly modelled on French pharmaceutical regulation; is the most EU-compatible clinical trial regulatory authority in the Arab world; DMP’s pharmaceutical expertise is underpinned by Morocco’s significant domestic pharmaceutical manufacturing sector (Morocco is one of Africa’s largest generic pharmaceutical manufacturers, exporting to Sub-Saharan Africa and the Middle East) whose regulatory sophistication elevates DMP’s institutional capacity above what its GDP-per-capita comparators would predict.
Morocco’s national biomedical research ethics committee; established under Law 28-13 (2015) as the national ethics oversight body for all biomedical research conducted in Morocco; providing national-level ethics review working in parallel with institutional ethics committees at CHU hospitals; CERB’s ethics review framework; operating under the Loi 28-13’s proportionate research category structure (interventional, minimal risk, non-interventional, analogous to France’s Loi Jardé categories I, II, and III); is the most structurally sophisticated national research ethics system in the Arab Maghreb, providing international sponsors with a predictable, category-based ethics review process whose conventions are directly familiar to French and Belgian pharmaceutical regulatory affairs teams.
Morocco’s Ministry of Health; overseeing the national CHU hospital network, national specialty institutes (INO, Hôpital des Spécialités, Hôpital Militaire d’Instruction Mohammed V through a separate MOD channel), national health insurance (AMO/RAMED), and the strategic planning of Morocco’s healthcare system expansion under the Couverture Médicale Universelle programme aiming for universal health coverage; the Ministry’s national healthcare transformation plan; investing in CHU capacity across all 12 regions; is progressively building the hospital infrastructure that will expand Morocco’s research geography beyond the Casablanca-Rabat-Fes triangle; RAMED (health insurance for the medically indigent) and AMO (mandatory health insurance for formal sector employees) together cover the majority of Moroccan citizens, creating a relatively structured healthcare registration system that facilitates patient identification for commercial Phase II–III trials.
Morocco’s oldest and most internationally connected medical school; affiliated with Université Mohammed V and producing the primary national investigator pipeline for Morocco’s CHU research network; with published research output spanning cardiovascular medicine, oncology, endocrinology, haematology, and North African pharmacogenomics; the FMPR’s active international research cooperation agreements; with French universities (Paris V, Paris VI, Lyon, Bordeaux), Belgian institutions (UCLouvain, ULB), and WHO; facilitate the cross-border academic collaborations through which European pharmaceutical companies engage Morocco’s academic investigator community; its advanced training programmes for clinical investigators; including formal GCP certification aligned with ICH E6(R2) and Law 28-13’s research governance framework; produce the certified investigator workforce that Morocco’s commercial Phase II–III portfolio requires.
Morocco’s most research-productive medical school per faculty output; affiliated with Sidi Mohammed Ben Abdallah University in Fes, Morocco’s historic intellectual capital; whose published pharmacogenomics research programme (NAT2 polymorphisms in Moroccan Amazigh TB patients; CYP2D6 and CYP2C19 variant frequencies in Moroccan Berber populations; G6PD deficiency in Moroccan communities) has established FMPM as the primary Moroccan academic institution in North African Amazigh pharmacogenomics research; FMPM’s CHU Hassan II affiliation and its Fes patient catchment from Morocco’s Atlas mountain Amazigh-majority communities create the academic-clinical research partnership that makes CHU Hassan II Fes the most important single site for commercial Amazigh pharmacogenomic sub-study programs; its international research network connections to French, Swiss, and Belgian pharmacogenomics research groups create the translational research channels that commercial sponsors use to design and interpret Moroccan pharmacogenomic sub-study protocols.
Morocco’s national infectious disease reference laboratory and research institution; a member of the Institut Pasteur International Network based in Casablanca; providing TB drug susceptibility testing, viral hepatitis surveillance, arboviral detection, and antimicrobial resistance monitoring across Morocco’s national laboratory network; Institut Pasteur du Maroc’s WHO EMRO (Eastern Mediterranean Regional Office) partnerships and Pasteur International Network connections link Moroccan infectious disease research to global TB, HIV, hepatitis, and emerging pathogen therapeutic development programmes; its biological safety laboratories, national pathogen reference collections, and epidemiological surveillance data provide the microbiological and virological research infrastructure that commercial infectious disease and TB Phase II–III trials require as companion diagnostics and microbiological endpoints.
Morocco’s national cancer institute; the custodian of Morocco’s national cancer registry and the primary Phase I–IV oncology clinical trial institution in the country; whose published cancer incidence data across all 12 Moroccan regions provides the population-based feasibility analysis foundation for commercial oncology trial activation decisions; INO’s Phase II–IV commercial trial portfolio; spanning breast cancer, haematological malignancies, colorectal cancer, and prostate cancer; is supported by active partnerships with French cooperative oncology groups, EORTC observer participation, and multinational pharmaceutical company relationships established through Casablanca’s Francophone Africa pharmaceutical industry hub; INO’s membership in Francophone oncology research networks creates trial access channels for French-language sponsors that the anglophone oncology research market’s cooperative groups do not cover.
Global CRO with Morocco operations based in Casablanca managing Phase II–IV programs across cardiovascular, oncology (INO platform and CHU network), metabolic disease, TB, and pharmacogenomics indications; DMP regulatory submission expertise and CERB ethics application support under Law 28-13’s framework, conducted in French; established investigator relationships across CHU Ibn Sina Rabat, INO, CHU Ibn Rochd Casablanca, CHU Hassan II Fes, and CHU Mohammed VI Marrakech; Francophone Africa regional coordination integrating Moroccan sites with Tunisia, Ivory Coast, Senegal, and Lebanon within pan-Francophone Phase III programs; MAD financial management for EUR/USD-budgeted sponsors; TB-specific trial management with NAT2 pharmacogenomic sub-study design expertise.
Global CRO with Moroccan operations providing Phase II–III trial management and DMP/Law 28-13 regulatory strategy across cardiovascular, oncology, metabolic disease, and pharmacogenomics indications; established site networks across the Casablanca-Rabat-Fes research triangle alongside CHU Mohammed VI Marrakech, CHU Souss-Massa Agadir, and CHU Mohammed VI Oujda for nationwide Morocco Phase III coverage; French-language trial documentation and CERB ethics submission expertise; Parexel’s Francophone MENA regulatory capability; for sponsors developing in French for pan-Maghreb or pan-Francophone Africa submissions; Amazigh pharmacogenomics sub-study design and biostatistics for North African Berber population multi-ancestry analyses.
International biopharmaceutical solutions company with Moroccan operations providing integrated Phase I–IV services across oncology, cardiovascular, TB, metabolic disease, and pharmacogenomics; French-language clinical operations expertise for DMP and CERB submissions under Law 28-13; INO oncology platform and CHU Ibn Sina national referral network site management; TB Phase II–III trial management integrating clinical endpoints with NAT2 pharmacogenomic sub-study designs specific to Morocco’s Amazigh-ancestry TB patient population; pan-Francophone MENA and Africa programme management coordinating Morocco within Tunisia, Ivory Coast, Senegal, and Lebanon integrated Phase III designs.
Sanofi; France’s largest pharmaceutical company; maintains one of the largest Moroccan operations of any multinational pharmaceutical company, reflecting the French pharmaceutical industry’s historical and ongoing engagement with Morocco’s Francophone research market; Sanofi Maroc’s established relationships with DMP, CERB, Morocco’s CHU network investigators, and INO; built through decades of commercial operations and clinical trial activations; represent the pharmaceutical industry’s most developed Law 28-13 research infrastructure in Morocco; alongside Roche Maroc, Novartis Maroc, GSK Maroc, AstraZeneca, and Pfizer’s Morocco operations; all based at Casablanca Finance City; the Francophone pharmaceutical industry’s deep Morocco engagement has created an investigator training, GCP culture, and regulatory submission experience infrastructure that makes Morocco an established, not emerging, Francophone pharmaceutical research market.
Morocco is the Maghreb’s indispensable clinical research market; a nation of 37 million whose Law 28-13 regulatory framework, Casablanca pharmaceutical industry hub, Amazigh pharmacogenomic research population, and three-city academic medical triangle create a Francophone research environment that no other Arab or African country combines in its totality. Law 28-13 is Morocco’s most immediately operationally distinctive asset: the Arab world’s only dedicated comprehensive biomedical research law explicitly modelled on France’s Loi Jardé, whose proportionate research category structure, CERB national ethics oversight, and French-language regulatory submission conventions make Morocco the Arab world’s most structurally EU-compatible research regulatory jurisdiction; a distinction that matters directly for French, Belgian, and Swiss pharmaceutical sponsors whose regulatory affairs teams are calibrated to Loi Jardé-type frameworks and for whom the alternative of adapting to Arabic-dominant or less-structured regulatory environments adds meaningful overhead to MENA market entry. Casablanca is Morocco’s most commercially consequential asset: Francophone Africa’s pharmaceutical industry hub, where Sanofi, Roche, Novartis, GSK, Pfizer, and AstraZeneca have established their Africa or MENA regional research and regulatory operations; creating a pre-built sponsor infrastructure of investigator networks, site feasibility databases, and regulatory submission experience that means first-time Morocco trial activations require substantially less institutional groundwork than first-time entries into Jordan, Tunisia, or Egypt. The Amazigh argument is Morocco’s most scientifically irreplaceable claim: 14–16 million people carrying NAT2, CYP2D6, CYP2C19, and G6PD pharmacogenomic profiles documented as distinct from Arab Gulf, Levantine Arab, and European reference populations; and accessible in concentration nowhere else in the world outside Morocco itself; whose pharmacokinetic data, for drugs metabolised through these pathways, is required for regulatory submissions targeting North African patient populations. The scale argument is Morocco’s most straightforward: at 37 million people, Morocco is three times Tunisia’s size, produces three times the patient volumes for every indication, and provides three times the enrollment velocity; while sharing Tunisia’s French language, comparable cost structure, and similar regulatory tradition; making Morocco the natural Maghrebi market for sponsors whose programs justify the research activation investment that Tunisia’s smaller patient base would not.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.